blood processing News
-
Seventh Sense Biosystems Expands to European Markets for Consumer Blood Collection with TAP II CE Marking
Seventh Sense Biosystems, Inc. (7SBio), developers of the world’s first push-button blood collection device, announced today that the company has received CE mark approval from the European Commission for its TAP® II blood collection device. This clearance opens up European Union markets for consumers and patients to access simple, convenient, and more comfortable blood collection ...
-
Seventh Sense Blood Collection Technology Key Part of Gateway Genomics’ SneakPeek Snap for Gender DNA Test
Making blood collection simpler, more convenient, and more comfortable. That’s our mission, and we are thrilled to share that our partner, Gateway Genomics, is leveraging our TAP II blood collection technology in its product offering, the SneakPeek Early Gender DNA Test. Called SneakPeek Snap, the blood collection device is included as part of the SneakPeek at-home blood collection kit. ...
-
Abram Scientific Secures $2.9 Million US Army Medical Research Grant to Deliver a Portable Viscoelastic, Blood Coagulation Diagnostic Platform for COVID-19 associated Coagulopathy Management
Abram Scientific today announced it has secured a $2.9 million US Army Grant in support of the company’s effort to address the COVID-19 pandemic. This grant supports the clinical development of the CoagCare System to screen for COVID-19 related blood clotting disorders or coagulopathies in patients. The CoagCare System is intended to aid in the evaluation of clotting disorders and help ...
-
Abram Scientific Secures $1 Million National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II Grant
Abram Scientific today announced it has secured a $2.9 million US Army Grant in support of the company’s effort to address the COVID-19 pandemic. This grant supports the clinical development of the CoagCare System to screen for COVID-19 related blood clotting disorders or coagulopathies in patients. The CoagCare System is intended to aid in the evaluation of clotting disorders and help ...
-
BrainScope Launches Next-Gen Medical Device: First and only FDA-cleared system for true point-of-care assessment of both concussion and brain bleeds now includes Concussion Index
BrainScope today announced the availability of its third groundbreaking FDA-cleared algorithm on the BrainScope device. The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at baseline, point of injury, and through recovery. The Concussion Index adds to the suite of FDA cleared algorithms already available on the ...
-
Gauss Surgical Announces $12.6 Million Series B Financing
Gauss Surgical, Inc., maker of Triton, the world’s first and only platform for real-time monitoring of surgical blood loss, today announced the close of its $12.6 million in Series B financing, bringing its total funding to $24.6 million. Providence Ventures, the investment arm of Providence Health & Services, the third largest not-for-profit health system in the United States, led the ...
-
Qvella Appoints Richard Brock as VP of Global Marketing and Signals Start of Commercialization
Qvella, a diagnostics company that aims to reduce the time to results in the diagnosis of infections, today announced that it has appointed Richard Brock as VP of Global Marketing. In this role, he will lead the imminent commercialization of Qvella’s FAST-Prep™ product for Positive Blood Culture (PBC) processing. He will be responsible for the company’s go-to-market and product ...
-
Fresenius Medical Care expands critical care offering with ExThera Medical’s Seraph 100 adsorber
Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, will offer the Seraph 100 Microbind Affinity Blood Filter from ExThera Medical Corporation in several European countries as of now. Both companies have signed a co-marketing and distribution agreement, effective in January 2021 and covering Belgium, Denmark, France, Germany, ...
-
Members of Congress Urge CMS to Take Action to Reduce Preventable False-Positive Diagnostic Test Results for Sepsis
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing1, commended U.S. Representatives Mike Levin (D-CA), Gus Bilirakis (R-FL), and eight of their colleagues for sending a joint, bipartisan letter urging the Centers for Medicare and Medicaid Services (CMS), an agency within ...
-
C2N Diagnostics Statement on FDA Accelerated Approval of Aducanumab forAlzheimer’s Treatment
C2N Diagnostics says the U.S. Food and Drug Administration’s (FDA) decision granting accelerated approval to aducanumab (Aduhelm) on the basis of amyloid plaque reduction for Alzheimer’s treatment represents a significant change in the ongoing fight against the horrible disease. Dr. Joel Braunstein, C2N’s CEO, said, “The accelerated approval of aducanumab will offer a ...
-
BrainScope Completes Agreement with 18,000 Member Yankee Alliance
BrainScope today announced a new system-wide agreement with Yankee Alliance to make BrainScope’s innovative point-of-care neuro-technology system available to the 18,000 members, including over 5000 outpatient facilities and senior centers, in Yankee Alliance. BrainScope is the only FDA cleared medical device that aids in the objective triage of head injured patients for suspected mild ...
-
It All Starts With Patient Safety at Medovate
When Medovate was spun out of the National Health Service (NHS) in 2017, one of the key priorities was to ensure that each medical device the company developed added real value to patient safety. The company mission is to “improve patient care and safety by supplying innovative Medtech solutions inspired by clinicians and developed in partnership with the NHS.” Through a unique ...
By Medovate
-
Understanding the different types of COVID-19 Testing
For COVID-19 testing, there are two predominant tests on the market: viral tests and serum antibody tests. Let’s take a look at the main differences between these two types of tests, like what they look for, when each is the most effective, and the logistics of providing each type. 1. Viral Tests Viral, or PCR, tests determine if an individual currently has COVID-19 by testing for the ...
By MiraDx
-
Abbott joins clinton health access initiative in effort to improve infant testing for HIV in Africa
Abbott and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI. A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children. Under terms of the agreement, Abbott will supply its RealTime ...
-
Focussing on Australia`s second biggest killer
The cluster will conduct the START (Stroke, imaging, pRevention and Treatment) cohort study of stroke which is designed to integrate imaging and biomarker analysis to identify patients at risk of stroke. Those strategies will then be used to develop preventative measures for those patients. The START Cohort will collect and analyse information derived from brain imaging and blood samples taken ...
-
Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections
CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds. Sepsis is the body’s overwhelming and life-threatening ...
-
Ground-breaking New Medical Device Saving Lives and Resources During Pandemic
A ground-breaking development in the detection of reduced lung function, as seen in COVID-19 patients, is saving lives, time, and resources. It’s thanks to the world’s first non-invasive lung function monitor, the MediPines AGM100®, developed in California, tested at University of British Columbia and Stevenson Memorial Hospital, and approved for use in Canada. Hospitals are ...
By MediPines
-
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in ...
-
Alzheimer’s Breakthrough: C2N First to Offer a Widely Accessible Blood Test
Who Want Earlier Answers Patients, advocates, and physicians who have long awaited an easy to administer blood test that can help them better understand Alzheimer’s disease now have a health care innovation which they can rely upon. A breakthrough in Alzheimer’s disease has arrived with the introduction of C2N Diagnostics’ PrecivityAD™ blood test into the clinic. ...
-
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG in 2H21, and clinical studies in additional cardiovascular ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you